- Home
- GNE vs LXRX Comparison
GNE vs LXRX Comparison
Compare GNE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNE
- LXRX
- Stock Information
- Founded
- GNE 2011
- LXRX 1995
- Country
- GNE United States
- LXRX United States
- Employees
- GNE N/A
- LXRX N/A
- Industry
- GNE Power Generation
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- GNE Utilities
- LXRX Health Care
- Exchange
- GNE Nasdaq
- LXRX Nasdaq
- Market Cap
- GNE 421.6M
- LXRX 352.5M
- IPO Year
- GNE N/A
- LXRX 2000
- Fundamental
- Price
- GNE $14.47
- LXRX $0.71
- Analyst Decision
- GNE
- LXRX Buy
- Analyst Count
- GNE 0
- LXRX 2
- Target Price
- GNE N/A
- LXRX $6.00
- AVG Volume (30 Days)
- GNE 89.2K
- LXRX 5.4M
- Earning Date
- GNE 11-06-2024
- LXRX 11-12-2024
- Dividend Yield
- GNE 2.07%
- LXRX N/A
- EPS Growth
- GNE N/A
- LXRX N/A
- EPS
- GNE 0.12
- LXRX N/A
- Revenue
- GNE $427,221,000.00
- LXRX $5,229,000.00
- Revenue This Year
- GNE N/A
- LXRX $886.38
- Revenue Next Year
- GNE N/A
- LXRX $181.58
- P/E Ratio
- GNE $120.30
- LXRX N/A
- Revenue Growth
- GNE 5.44
- LXRX 886.60
- 52 Week Low
- GNE $14.00
- LXRX $0.62
- 52 Week High
- GNE $30.90
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- GNE 37.63
- LXRX 36.95
- Support Level
- GNE $14.39
- LXRX $0.66
- Resistance Level
- GNE $15.09
- LXRX $0.85
- Average True Range (ATR)
- GNE 0.39
- LXRX 0.10
- MACD
- GNE 0.00
- LXRX 0.02
- Stochastic Oscillator
- GNE 13.96
- LXRX 23.67
About GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.